###### Strengths and limitations of this study

-   Simple adjustment of laboratory method allowed detection of methicillin-susceptible *Staphylococcus aureus* (MSSA) as well as methicillin-resistant *S. aureus*.

-   Decolonising MSSA-positive orthopaedic patients before surgery protected them from deep MSSA infection in bone and joints.

-   The study highlights an important and costly deficit in the current national screening tool for high-risk surgery.

-   Study limited due to one site setting in Scotland.

-   Costs based on UK National Health Service (NHS) practices only.

Introduction {#s1}
============

Approximately one in three people are colonised with *Staphylococcus aureus* (methicillin-susceptible *S. aureus*, MSSA) in contrast to the current low rate of methicillin-resistant *S. aureus* (MRSA) colonisation in the UK.[@R1] Carriage is genetically determined and represents a risk for infection, especially when admitted to hospital for surgery. Endogenous MSSA is a common cause of postoperative infection.[@R1] [@R2] This risk is recognised by choice of specific antistaphylococcal antibiotics for surgical prophylaxis, especially high-risk procedures such as orthopaedic and vascular implant surgeries.[@R3] [@R4]

Concern over increasing MRSA led to the introduction of a national MRSA screening programme for all hospital admissions, including elective surgical patients.[@R5] The subsequent increase in screening swabs meant that laboratories had to streamline their methods and MRSA chromogenic agar was chosen to aid rapid identification.[@R5] Unfortunately, this agar cannot yield MSSA. Thus, a patient might be deemed negative for MRSA carriage but could still be positive for MSSA. If elective patients awaiting orthopaedic implant surgery demonstrate MSSA carriage then they are known to be at risk of postoperative MSSA infection.[@R2] [@R3]

Owing to ongoing sporadic MSSA infections among orthopaedic patients, our health board approved the decision to broaden preoperative screening to include MSSA as well as MRSA for elective implant patients from December 2013. Trauma patients receive immediate care and proceed to surgery without prior screening. This paper describes an audit of postoperative staphylococcal infection among all elective and trauma orthopaedic patients at one hospital within two separate 6-month periods: January to June 2013 (period A: MRSA screening only) and January to June 2014 (period B: screening for MSSA and MRSA). We compare and contrast the MSSA infection rate between all patients receiving orthopaedic surgery during both study periods and present an evaluation of the change to health service costs from a decision to adopt the enhanced screening programme.

Methods {#s2}
=======

The study hospital is a 550-bed acute district general hospital with 24-hour accident and emergency (A&E) department. The hospital offers a range of services including management of elective and trauma patients for orthopaedic surgery. Trauma patients are admitted through A&E and receive immediate surgery if appropriate. Elective patients attend the preassessment clinic for evaluation of surgical fitness, including MRSA screening in accordance with national protocol.[@R5] Orthopaedic services are delivered by four consultants responsible for \>95% of all implant surgeries undertaken by the hospital, which is the largest orthopaedic referral centre for the health board. A number of severe MSSA implant infections occurred in 2012, unrelated in time or space. It was decided to pilot an enhanced screening programme managed by preassessment for 3 months (July to September) in 2013 and audit the effect. Thus, patients were swabbed as usual (nasal, perineal±wounds) and request forms were tagged so that the laboratory could distinguish specimens from orthopaedic patients and process them for MSSA as well as MRSA. In the event of cancellation of surgery, some patients were recalled for repeat screening.

Laboratory methods {#s2a}
------------------

Swabs were transported to the laboratory and processed on the day of collection. Standard operating protocol was changed to encompass preliminary isolation of *S. aureus* by switching from MRSA chromogenic to *S. aureus* identification (SAID) chromogenic agar. Characteristic blue colonies were further tested for coagulase production (Staphylase) and indeterminate reactions were confirmed with tube coagulase. Positive isolates were characterised by automated technology (Vitek) including antibiotic susceptibilities. The results were authorised by the consultant microbiologist who reported appropriate susceptibilities (flucloxacillin; clarythromycin; vancomycin; gentamicin and mupirocin).

Patient decolonisation {#s2b}
----------------------

Authorised results were fed back to preassessment. A standard letter detailing MSSA isolation and management options was sent to the orthopaedic consultant responsible for the patient. Confirmed MSSA carriage at skin sites was treated with 5 days Naseptin (chlorhexidine hydrochloride 0.1%; neomycin sulfate 0.5%) nasal cream applied three times a day and daily chlorhexidine gluconate 4% body washes. MRSA-positive patients received the same regimen but with mupirocin 2% (Bactroban) nasal cream rather than Naseptin. A known MSSA-positive patient would occasionally present for surgery without having received any clearance therapy; these patients were offered preoperative Naseptin and a chlorhexidine shower. MRSA-positive patients were deferred from surgery unless they had received the appropriate decolonisation protocol. Surgical prophylaxis for all orthopaedic patients was flucloxacillin±gentamicin or a glycopeptide, in accordance with local prescribing policy.

Audit strategy {#s2c}
--------------

Following encouraging results from the 3-month pilot study, additional MSSA screening for elective orthopaedic patients was implemented from mid-December 2013. We decided to conduct a formal audit of patient outcome in order to evaluate the screening programme. Two periods were chosen: the first 6 months in 2013, when only MRSA screening was performed, and the same 6-month period in 2014, when both MSSA and MRSA screenings were performed. These periods were chosen to reflect seasonal variation, bypass the effect from the 2013 pilot study and permit sufficient 'wash-out' time between old and new screening policies. We included orthopaedic trauma patients admitted during the same periods as control because these patients proceed to immediate surgery without screening. There were no policy changes in the management of either trauma or elective orthopaedic patients during the study period, including estates-related or infection control programmes.

Data retrieval {#s2d}
--------------

The hospital database was searched for all orthopaedic patients attending preassessment from 1 January to 1 July 2013 (period A) and for the same 6-month period (period B) the following year, 2014. A separate search of the microbiology database yielded every orthopaedic patient submitting one or more samples requesting a test for, or positive for, *S. aureus* from 1 January 2013 until 31 December 2014. Patients were then cross-checked against microbiology and hospital records in order to identify all elective and trauma patients presenting within the two periods; those screened for MRSA, those screened for MSSA and MRSA, patients colonised with MRSA or MSSA; and all patients identified with postoperative staphylococcal infection within 1 month after surgery (early-onset) or after 1 month following surgery (late-onset). Patients were followed up for 1 year after surgery. New patients presenting outside the two study periods were excluded. Postoperative patients who missed prior screening and subsequently developed infection were offered relevant screening. The number of return trips to the operation theatre, additional surgical interventions, intensive care unit (ICU) admission, A&E and outpatient attendance, microbiological investigations and length of stay (LOS) were documented for all patients with postoperative infection.

Cost data for screening activities and for laboratory and clinical management of infection were obtained from a number of resources, both local and national. Laboratory consumables were recovered from manufacturers\' data at nationally agreed National Health Service (NHS) cost; biomedical scientist, hospital consultant, general practitioner (GP) and nurse time costs were based on national pay scales, with mid-point values selected for calculation. Health board data were used to estimate the costs of laboratory processing for individual tests, such as wound swabs, blood cultures and aspirates, etc. These included consumables, staff time, laboratory overheads (including quality control, training and waste disposal) and specimen transport. The costs of all antimicrobial drugs and other products were retrieved from the 2015 British National Formulary (BNF) Online database at <http://www.bnf.org/products/bnf-online/>. Clinical costs, such as ICU, hospital bed-days, surgical procedures and outpatient and A&E attendances were taken from NHS Scotland Tariffs published data (2013/2014) available via: <http://www.isdscotland.org/Health-Topics/Finance/Scottish-National-Tariff/>

Infection definitions {#s2e}
---------------------

Each patient with postoperative MSSA infection was investigated to ascertain the severity of infection and subsequent management.[@R6] 'Superficial' surgical site infection was defined as skin and soft tissue involvement only; 'deep' infection (also organ/space infection) was defined as infected implant necessitating intravenous antibiotics and further surgery. Patients with postoperative staphylococcal infections unrelated to the surgical site were not included.

Since it was not possible to calculate the total number of trauma patients presenting at the A&E department during the study periods, we selected all those who received emergency surgery in trauma theatre. This provided the denominator for sepsis rates among trauma patients during both study periods. We were able to ascertain the total number of elective patients who attended preassessment and this was used to calculate the overall sepsis rates among elective orthopaedic patients for both study periods.

Statistical analysis {#s2f}
--------------------

CIs for the risk ratio were calculated using exact sample methods. Wilson\'s limit was used for the CIs for the proportion. Tests of association were carried out using Fisher\'s exact test. The joint effects of elective compared with trauma surgery and period were investigated through a logistic regression using a log link. R V.3.2 was used for the analysis, together with the epitools and Hmisc libraries.

Cost modelling {#s2g}
--------------

The expected change to total health services costs were modelled for a cohort of 500 elective orthopaedic patients. The extra costs from additional MSSA screening were included as were the cost-savings from changes to the number of cases of superficial and deep infection. All data uncertainties were included by fitting prior statistical distributions and running a probabilistic analysis of 1000 simulations. Parameters that describe the costs of additional MSSA screening ([table 1](#BMJOPEN2016011642TB1){ref-type="table"}) had uncertainties represented by a 10% positive and negative variance. Information on the resources used and subsequent treatment costs ([table 2](#BMJOPEN2016011642TB2){ref-type="table"}; see online [supplementary appendices](#SM1){ref-type="supplementary-material"} 1--3) for cases of deep infection were used to update a prior γ distribution to show the costs of treating a case of deep infection. The cost of treating a superficial infection is shown in online [supplementary appendix](#SM1){ref-type="supplementary-material"} 4 and uncertainties were represented by a 10% positive and negative variance. The relative risk of infection from additional screening over baseline screening was estimated from the data in [table 3](#BMJOPEN2016011642TB3){ref-type="table"}. Prior uncertainties (online [supplementary appendices](#SM1){ref-type="supplementary-material"} 5 and 6) were specified with a statistical distribution using calculated log relative risk and SE. Applying the starting risk of infection shown in [table 3](#BMJOPEN2016011642TB3){ref-type="table"} under conditions of baseline screening provides estimates of the starting numbers of infections among the cohort. These were modified by the uncertain relative risks shown in online [supplementary appendices](#SM1){ref-type="supplementary-material"} 4 and 5 to predict the change in the number of infections (see online [supplementary appendices](#SM1){ref-type="supplementary-material"} 7 and 8). The expected cost of the enhanced screening (see online [supplementary appendix](#SM1){ref-type="supplementary-material"} 9) and the change in total costs was estimated.
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###### 

Additional costs of enhanced staphylococcal screening

  Activity                  Resources                                                                   Quantity/price
  ------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  Preassessment screening   Swabs (nasal; perineal; ±wounds; urine)                                     NAC
                            Patient counselling; swabbing; writing laboratory form; tag patient notes   NAC
  Laboratory process        Transport and booking                                                       NAC
                            Urine microscopy; swabs plated out onto agar                                NAC
                            Identify and confirm colonies with Staphylase kit                           £103/kit, £0.035 per test
                            Purity plate (blood agar)                                                   BA plate: £0.18 test
                            VITEK ID and susceptibilities; reagents and BMS time                        Vitek Card £4.00, CLED purity plate £0.17, consumables £0.30, 25 min BMS time £6.33
  Reporting                 Microbiologist                                                              1 hour (medic) £55, 5 min to authorise
                            Preassessment action (staff time)                                           1 hour (band 5 nurse): £12.50, 10 min per patient
  Topical clearance         Consultant alert and action                                                 1 hour (medic) £55, 5 min
                            Secretarial GP letter                                                       1 hour (secretary) £9.00, 5 min
                            GP action                                                                   1 hour (salaried GP): £35, 10 min
                            Naseptin (5 days)                                                           £2.45 per tube
                            Chlorhexidine gluconate 4% bath (5 days)\*                                  £5.25 per 500 mL

\*Not all patients received the full 5 day course of chlorhexidine washes.

GP, general practitioner; NAC, no additional cost.

###### 

Outcome of 16 postoperative deep MSSA infections among elective orthopaedic surgery patients during two 6-month periods (2013--2014)

  Year   Site    Management                                 Other                       LOS   OPD
  ------ ------- ------------------------------------------ --------------------------- ----- -----
  2013   Hip     Failed DAIR → 1-stage                      ICU 3d                      53    4
  2013   Knee    DAIR → revision TKR                        --                          19    0
  2013   Ankle   Failed DAIR ×2 → failed 2-stage → fusion   Osteomyelitis               313   8
  2013   Tibia   Failed DAIR ×2 → metal removed             A&E                         7     9
  2013   Ankle   Failed DAIR ×3 → failed 2-stage            Osteomyelitis               30    19
  2013   Hip     Failed DAIR ×2 → revision                  ICU 6d; positive BLC        40    12
  2013   Hip     Failed DAIR                                A&E; ICU 5d; positive BLC   16    1
  2013   Knee    Failed DAIR → revision                     A&E                         40    7
  2013   Tibia   Failed DAIR → metal removed                --                          12    5
  2013   Knee    Revision TKR                               --                          4     5
  2013   Hip     Revision THR                               A&E ×3; C.diff; ICU 2D      49    0
  2013   Ankle   DAIR                                       A&E                         6     1
  2013   Toe     Failed DAIR ×2 →                           A&E                         11    10
  2013   Knee    Failed DAIR                                --                          4     3
  2013   Ankle   DAIR → metal removed                       ICU 8d                      8     4
  2014   Ankle   DAIR                                       Positive BLC                26    1

A&E, accident and emergency; BLC, blood cultures; C. diff, *Clostridium difficile*; DAIR, debridement-antibiotics-implant retention; ICU, intensive care unit; LOS, length of stay; MSSA, methicillin-susceptible *Staphylococcus aureus*; OPD, outpatient department; THR, total hip revision; TKR, total knee revision.

###### 

MSSA infection outcome of all orthopaedic patients during two 6-month periods

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                                  Period A\               Period B\                                                                       
                                  January to June 2013\   January to June 2014\                                                           
                                  No MSSA screen          MSSA screen (elective patients only)                                            
  ------------------------------- ----------------------- -------------------------------------- -------------- ------------- ----------- ------------
  MSSA screening                  No screen               No screen                              No screen      MSSA Neg\     MSSA Pos\   No screen\
                                                                                                                218 (71%)     89 (29%)    NK

  No MSSA infection†              435 (97.31%)            213 (91.81%)                           343 (97.44%)   215 (97.7%)   85          NK

  Superficial MSSA infection‡     2 (0.45%)               4 (1.72%)                              4 (1.14%)      2 (0.7%)      4 (1.3%)    0 (0%)

  (postoperative MSSA carriage)   \(0\)                   \(1\)                                  \(1\)          (1§)          (4¶)        \(0\)

  Deep MSSA infection\*\*         10 (2.24%)              15 (6.47%)                             5 (1.42%)      1†† (0.3%)    0 (0%)      4 NK%

  (postoperative MSSA carriage)   \(1\)                   (7§)                                   \(2\)          \(0\)                     \(2\)
  ----------------------------------------------------------------------------------------------------------------------------------------------------

Among elective patients the risk ratio of any MSSA infection was 0.28 (95% CI 0.12 to 0.65) in period B compared with period A; risk ratio of any MSSA infection was 0.95 (95% CI 0.41 to 2.23) in period B compared with period A.

\*Unscreened patients admitted for surgery from outpatients or another hospital.

†Excluding patients presenting at another hospital.

‡Superficial infection: skin and soft tissue only.

§Original screen negative (one patient); positive for MSSA postsurgery.

¶All four patients had superficial MSSA infection with strains resembling nasal isolates.

\*\*Deep infection: intravenous antibiotics+further surgery.

††Patient screened twice for MSSA but no evidence of carriage.

MSSA, methicillin-susceptible *Staphylococcus aureus*; Neg, negative; NK, not known; Pos, positive.

Results {#s3}
=======

During 1 January to 1 July 2013 (period A), 232 patients underwent preoperative assessment before elective orthopaedic surgery compared with 307 patients during 1 January to 1 July 2014 (period B; [table 3](#BMJOPEN2016011642TB3){ref-type="table"}). Over the same two 6-month periods, 447 patients received emergency orthopaedic surgery during period A compared with 352 patients during period B. There were also an unknown number of patients admitted directly from outpatient clinics or transferred from other hospitals who underwent orthopaedic surgery ([table 3](#BMJOPEN2016011642TB3){ref-type="table"}).

During period A, 2 (0.45%) and 10 (2.24%) of 447 trauma patients had superficial MSSA and deep MSSA infections, respectively. These were similar to infection rates for trauma patients during period B (superficial: 4 of 352 (1.14%); deep: 5 of 352 (1.42%); p=1, Fisher\'s exact test; [table 3](#BMJOPEN2016011642TB3){ref-type="table"}). Of the 232 elective patients in period A, 4 (1.72%) patients had superficial MSSA and 15 (6.47%) had deep MSSA infections following implant surgery; during period B, 6 (2%) of 307 elective patients had superficial MSSA infection with just 1 (0.3%) deep infection (p=0.002; [table 2](#BMJOPEN2016011642TB2){ref-type="table"} and [3](#BMJOPEN2016011642TB3){ref-type="table"}). There is a significant interaction between trauma and elective surgery and each period on the risk of MSSA infection (p=0.044). Among trauma patients the risk ratio of any MSSA infection was 0.95 (95% CI 0.41 to 2.23) in period B compared with period A, while the corresponding risk ratio was 0.28 (95% CI 0.12 to 0.65) for elective patients. For deep MSSA infections, the risk ratio was 0.58 (95% CI 0.20 to 1.67) for trauma patients and 0.05 (95% CI 0.01 to 0.36) for elective patients (p=0.011). Four additional deep MSSA infections were identified during period B in patients who had not attended preassessment or received prior screening ([table 3](#BMJOPEN2016011642TB3){ref-type="table"}). They are not included in the above analysis.

Of the 307 patients screened by preassessment in period B, 89 (29%, 95% CI 24% to 34%) were identified as carriers. This supports the premise that around one-third of people are colonised with coagulase-positive staphylococci.[@R1] There was only 1 (0.3%) deep MSSA infection among the 307 screened elective patients, whereas there were 30 (2.9%) deep MSSA infections among all the unscreened patients (n=1031), whether managed as elective or trauma ([table 3](#BMJOPEN2016011642TB3){ref-type="table"}). Formal comparison of patient cohorts is not considered further because we did not adjust for operation type, age or length of operation, all of which differ between trauma and elective patients. Although the numbers are small, elective patients were 2.89 times (95% CI 1.32 to 6.33; p=0.009) more likely than trauma patients in period A to suffer deep MSSA infection (elective 6.47% vs trauma 2.24%).

Patients with confirmed postoperative MSSA infection (superficial and deep) who missed prior MSSA screening were investigated further. Of the 44 patients with MSSA infection, 17 were screened and 14 of these demonstrated nasal MSSA ([table 3](#BMJOPEN2016011642TB3){ref-type="table"}). These figures include four elective patients admitted during period B who did not attend preassessment. There were three patients deemed negative following prior screening who suffered postoperative MSSA infection. Repeat nasal screening after confirmation of postoperative MSSA infection then established presence of MSSA.

Before and throughout the entire study period, patients were screened for MRSA in accordance with national guidelines.[@R5] This occurred for elective patients before surgery but trauma patients usually received surgery before the screening took place. The number of MRSA infections among orthopaedic patients was negligible for both periods (A: one patient; B: no MRSA infections), although superficial carriage was occasionally identified. There were no patients with both MSSA and MRSA at the same time. Given that there were so few MRSA infections, these patients are not considered further.

Cost modelling {#s3a}
--------------

We estimate that enhanced screening costs £18 269 for 500 patients screened ([table 4](#BMJOPEN2016011642TB4){ref-type="table"}). There would be an additional 3.04 superficial infections arising but 29.12 fewer deep infections. The overall change in costs would be savings of £831 678; this is caused by the high costs of treating a deep infection that are avoided due to enhanced screening (see online [supplementary appendix](#SM1){ref-type="supplementary-material"} 3). The uncertainty in the estimated change in total cost is shown in [figure 1](#BMJOPEN2016011642F1){ref-type="fig"}. Interpreting this plot for decision-making suggests there is an 86.8% chance that implementing enhanced screening is cost-saving. A rational and risk neutral decision maker should adopt enhanced screening, and on average this will yield a saving of £831 678 per 500 patients screened.

###### 

Statistical summary of relative risks, screening costs, infections prevented and potential cost-savings

                                                                  Minimum       Maximum      Median      Mean
  --------------------------------------------------------------- ------------- ------------ ----------- -----------
  Relative risk superficial                                       0.14          10.10        1.21        1.48
  Relative risk deep                                              0.00          2.34         0.05        0.09
  Costs of screening                                              £17 069       £19 356      £18 284     £18 269
  Superficial infections prevented\*                              −78.46        7.42         −1.84       −4.13
  Deep infections prevented\*                                     −43.42        32.22        30.67       29.37
  Potential cost-savings from superficial infections prevented†   −£9957        £943         −£231       −£524
  Potential cost-savings from deep infections prevented†          −£3 473 254   £3 360 145   £830 758    £833 334
  Change to total costs†                                          −£3 342 107   £3 491 865   −£812 559   −£814 541

\*Positive numbers mean cases are prevented.

†Negative numbers mean costs are saved.

![Figure showing uncertainty in estimated change to total cost with enhanced screening of elective orthopaedic patients awaiting implant surgery. The area to the left of the dashed line is 86.8% of the distribution. This means that there is an 86.8% chance that implementing enhanced screening is cost-saving (see text).](bmjopen2016011642f01){#BMJOPEN2016011642F1}

Discussion {#s4}
==========

Given the focus on MRSA, it is not surprising that MSSA infections have continued unabated in UK hospitals. While the rate of MRSA bacteraemia has been decreasing since 2008, the MSSA bacteraemia rate has continued with little change.[@R7] [@R8] This study investigated patients receiving orthopaedic implant surgery, and found that MSSA carriage remains an important risk factor for postoperative infection, whether admitted for trauma or as a planned elective.

Most of the infections identified during the period without MSSA screening were classified as 'deep', which mandated the need for further surgery. Previous reports state that the average cost of a failed implant varies from £7000 to £36 000 depending on the site, debridement, antibiotics and/or revision surgery.[@R9] [@R10] These figures do not necessarily include extra LOS. We found that the average total cost of managing a deep MSSA implant infection occurring in period A was about £55 500, which exceeds the figures quoted. Since we included parameters such as LOS, intensive care days, microbiological tests, A&E and outpatient attendance, it is possible that our figures are a more realistic illustration of additional costs due to postoperative orthopaedic infection. A recent paper from a London teaching hospital (with a domiciliary antibiotic facility) found that the average LOS for 45 patients needing total knee arthroplasty was 21.49 days.[@R10] Our 16 patients had an average LOS of 40 days ([table 2](#BMJOPEN2016011642TB2){ref-type="table"}), although if one single patient who stayed in hospital for 313 days is removed, 15 patients had an average LOS of 21.3 days, which is similar to the London hospital data.

There are caveats to our findings when balancing cost-savings from fewer failed implants against the screening costs ([table 1](#BMJOPEN2016011642TB1){ref-type="table"}). Broadening laboratory protocols to include MSSA identification were cost neutral due to the use of less expensive agar, but there were additional administrative and managerial costs for preassessment, orthopaedic secretaries and clinicians. Most of the product costs were absorbed by the hospital (nasal creams and antiseptic washes) but some patients obtained a prescription from their GP. Furthermore, some operations were postponed, in which case the patients concerned were asked to attend preassessment for repeat screening. Given this, it is possible that the overall cost of the screening programme (∼£18 000) may have been underestimated. The savings made from reduced numbers of deep orthopaedic infections were substantial, however, and it is assumed that they more than covered the costs of the screening initiative.[@R11] [@R12]

The study has some strengths and limitations. Simple adjustment of laboratory method allowed detection of MSSA as well as MRSA without compromising laboratory staff or usual practices. The amendment to standard operating procedure was cost neutral. Decolonising MSSA-positive orthopaedic patients before surgery appeared to protect them from deep MSSA infection in bone and joints, although we accept the causal nature of the association. The study highlights an important and costly deficit in the current national staphylococcal screening tool for high-risk surgery. The findings are limited due to the single site setting in a relatively deprived area of Scotland, however, and the fact that costs are based on UK NHS practices only. This means that the reported outcome may not apply to other orthopaedic units, although they may be relevant during an 'outbreak' situation.

MSSA isolates were not retained for further molecular characterisation so we could not demonstrate identity between colonising and infecting strains in the same patient. This was due in part to the retrospective audit for period A. There have been many previous studies demonstrating genotypic links between colonising strains and postsurgical infection due to the carrier strain.[@R1] [@R11] We had no wish to duplicate this work. However, we did notice indistinguishable antibiograms between MSSA isolates recovered from screening swabs and those submitted days or weeks later from samples taken to confirm postoperative infection. Occasionally, there were multiple samples from the same patient, including blood cultures, aspirate and tissues, taken before or during revision surgery that generated unique antimicrobial susceptibility patterns, including minimal inhibitory concentration (MIC) values, to key antibiotics. We believe that patients habitually colonised with their own unique strain are at risk from infection due to their carried strain when compromised by a major surgical intervention.[@R1] Three patients, originally negative for MSSA carriage, were found to be positive following confirmation of postoperative MSSA infection. They may illustrate transient staphylococcal carriage, which also poses an infection risk for surgical patients.[@R1] An alternative explanation is that original screening swabs did not detect a colonising strain; or it failed to grow, or was overlooked by the laboratory. PCR might ameliorate some false-negative results, but this method requires costly consumables and delivers increased numbers of false positives.[@R13]

MRSA bacteraemia rates have fallen across the UK over the past 10 years.[@R7] This fall may be attributable to the universal MRSA screening programme, which recommends the use of MRSA chromogenic agar.[@R14] Selective agar facilitates the identification of MRSA but inhibits the growth of MSSA. This might explain why MRSA bacteraemia rates have reduced in the UK, whereas MSSA rates have not. These trends contrast with those in Australia, where MRSA chromogenic agar is not universally employed and both MRSA and MSSA rates have decreased in parallel over the same time period.[@R15]

In conclusion, broadening the national screening policy to include MSSA for elective orthopaedic surgery patients awaiting implant procedures identified preoperative carriage in nearly one-third of the patients. The screening programme may have facilitated a reduction in deep postoperative infection in the screened patient cohort. The cost-benefits from enhanced screening in this high-risk population of surgical patients are substantial.[@R12]
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